Form 4: Director Karen Lynch Acquires Thermo Fisher Phantom Stock

Thermo Fisher Scientific Director Karen S. Lynch acquired 53.93 phantom stock units as part of the company's Deferred Compensation Plan for Directors.

Summary

• Karen S. Lynch, a Director at Thermo Fisher Scientific Inc. (TMO), acquired 53.93 phantom stock units.
• The acquisition occurred on December 31, 2025, at a price of $579.45 per unit.
• These units were credited to her account under the Issuer's Deferred Compensation Plan for Directors.
• Directors' retainers are deferred quarterly into Common Stock units based on the stock's closing price at quarter-end.
• The phantom stock units are convertible into Common Stock on a 1-for-1 basis.
• Following this transaction, Karen S. Lynch beneficially owns 225.47 derivative securities (phantom stock units).
• The shares are distributable as stock upon cessation of director service or a change of control.

Sentiment

Score: 6

Explanation: Slightly positive as it indicates a director's increased alignment with shareholder interests through a deferred compensation plan, which is a standard corporate governance practice.

Positives

• Director Karen S. Lynch increased her beneficial ownership of phantom stock units, aligning her interests with shareholders.
• The transaction is part of a structured Deferred Compensation Plan for Directors, indicating a standard corporate governance practice.

Future Outlook

The filing does not contain forward-looking statements regarding the company's financial performance or strategic outlook, focusing solely on an insider transaction.

Industry Context

This Form 4 filing details a routine insider transaction related to director compensation, a common practice across publicly traded companies to align director interests with shareholders. It does not provide insights into broader industry trends or competitive landscape.

Corporate Governance

Related Party Transactions

• Acquisition of phantom stock units by a director under the company's Deferred Compensation Plan for Directors.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with shareholders due to stock-based compensation.
• Director (Karen S. Lynch): Receives deferred compensation in the form of phantom stock units, which will convert to common stock upon specific events.

Next Steps

• The phantom stock units will be distributable as stock upon cessation of director service or a change of control.

Key Dates

Keywords

Thermo Fisher Scientific, TMO, Karen S. Lynch, Form 4, Insider Transaction, Phantom Stock Units, Director Compensation, Deferred Compensation Plan, Corporate Governance, SEC Filing